Launch of Rienso® ▼ (Ferumoxytol) Offers Adult Patients with Chronic Kidney Disease a New Option for the Treatment of Iron Deficiency Anaemia

Launch of Rienso® ▼ (Ferumoxytol) Offers Adult Patients with Chronic Kidney Disease a New Option for the Treatment of Iron Deficiency Anaemia PR Newswire ZURICH, November 1, 2012 ZURICH, November 1, 2012 /PRNewswire/ -- ®Today, Takeda Pharmaceuticals International GmbH (Takeda) announced the launch of Rienso (ferumoxytol) in the UK, a new intravenous (IV) iron therapy to treat iron deficiency anaemia (IDA) in adult patients with chronic kidney disease (CKD). This follows marketing authorisation granted by the European Commission (EC) in June 2012. Clinical studies demonstrated that Rienso significantly increases haemoglobin levels as compared to oral iron across [1],[2],[3]the spectrum of CKD. Moreover, Rienso was well tolerated by CKD patients with IDA and had an overall treatment-related adverse event rate similar to oral iron treatment based on data from three pivotal Phase III studies [1],[2],[3]involving 1,726 subjects. These outcomes were further supported by additional retrospective observational data from three large haemodialysis studies conducted in the United States involving more than 8,600 patients and more [4],[5]than 33,300 administered doses of Rienso.